Cargando…

Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children

BACKGROUND: Compared with the general population, the immune response to COVID-19 mRNA vaccines is lower in adult kidney transplant recipients (KTRs). However, data is limited for pediatric KTRs. In this study, we aimed to assess humoral and cellular immune responses to the COVID-19 mRNA vaccine in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulmez, Ruveyda, Ozbey, Dogukan, Agbas, Ayse, Aksu, Bagdagul, Yildiz, Nurdan, Uckardes, Diana, Saygili, Seha, Yilmaz, Esra Karabag, Yildirim, Zeynep Yuruk, Tasdemir, Mehmet, Kiykim, Ayca, Cokugras, Haluk, Canpolat, Nur, Nayir, Ahmet, Kocazeybek, Bekir, Caliskan, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716124/
https://www.ncbi.nlm.nih.gov/pubmed/36459243
http://dx.doi.org/10.1007/s00467-022-05813-w
_version_ 1784842613358067712
author Gulmez, Ruveyda
Ozbey, Dogukan
Agbas, Ayse
Aksu, Bagdagul
Yildiz, Nurdan
Uckardes, Diana
Saygili, Seha
Yilmaz, Esra Karabag
Yildirim, Zeynep Yuruk
Tasdemir, Mehmet
Kiykim, Ayca
Cokugras, Haluk
Canpolat, Nur
Nayir, Ahmet
Kocazeybek, Bekir
Caliskan, Salim
author_facet Gulmez, Ruveyda
Ozbey, Dogukan
Agbas, Ayse
Aksu, Bagdagul
Yildiz, Nurdan
Uckardes, Diana
Saygili, Seha
Yilmaz, Esra Karabag
Yildirim, Zeynep Yuruk
Tasdemir, Mehmet
Kiykim, Ayca
Cokugras, Haluk
Canpolat, Nur
Nayir, Ahmet
Kocazeybek, Bekir
Caliskan, Salim
author_sort Gulmez, Ruveyda
collection PubMed
description BACKGROUND: Compared with the general population, the immune response to COVID-19 mRNA vaccines is lower in adult kidney transplant recipients (KTRs). However, data is limited for pediatric KTRs. In this study, we aimed to assess humoral and cellular immune responses to the COVID-19 mRNA vaccine in pediatric KTRs. METHODS: This multicenter, prospective, case–control study included 63 KTRs (37 male, aged 12–21 years), 19 dialysis patients, and 19 controls. Humoral (anti-SARS-CoV2 IgG, neutralizing Ab (nAb)) and cellular (interferon-gamma release assay (IGRA)) immune responses were assessed at least one month after two doses of BNT162b2 mRNA vaccine. RESULTS: Among COVID-19 naïve KTRs (n = 46), 76.1% tested positive for anti-SARS-CoV-2 IgG, 54.3% for nAb, and 63% for IGRA. Serum levels of anti-SARS-CoV-2 IgG and nAb activity were significantly lower in KTRs compared to dialysis and control groups (p < 0.05 for all). Seropositivity in KTRs was independently associated with shorter transplant duration (p = 0.005), and higher eGFR (p = 0.007). IGRA titer was significantly lower than dialysis patients (p = 0.009). Twenty (43.4%) KTRs were positive for all immune parameters. Only four of 11 seronegative KTRs were IGRA-positive. COVID-19 recovered KTRs had significantly higher anti-SARS-CoV-2 IgG and nAb activity levels than COVID-19 naïve KTRs (p = 0.018 and p = 0.007, respectively). CONCLUSIONS: The humoral and cellular immune responses to SARS-CoV-2 mRNA BNT162b2 vaccine are lower in pediatric KTRs compared to dialysis patients. Further prospective studies are required to demonstrate the clinical efficacy of the mRNA vaccine in KTRs. This prospective study was registered in ClinicalTrials.gov (NCT05465863, registered retrospectively at 20.07.2022). GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00467-022-05813-w.
format Online
Article
Text
id pubmed-9716124
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97161242022-12-02 Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children Gulmez, Ruveyda Ozbey, Dogukan Agbas, Ayse Aksu, Bagdagul Yildiz, Nurdan Uckardes, Diana Saygili, Seha Yilmaz, Esra Karabag Yildirim, Zeynep Yuruk Tasdemir, Mehmet Kiykim, Ayca Cokugras, Haluk Canpolat, Nur Nayir, Ahmet Kocazeybek, Bekir Caliskan, Salim Pediatr Nephrol Original Article BACKGROUND: Compared with the general population, the immune response to COVID-19 mRNA vaccines is lower in adult kidney transplant recipients (KTRs). However, data is limited for pediatric KTRs. In this study, we aimed to assess humoral and cellular immune responses to the COVID-19 mRNA vaccine in pediatric KTRs. METHODS: This multicenter, prospective, case–control study included 63 KTRs (37 male, aged 12–21 years), 19 dialysis patients, and 19 controls. Humoral (anti-SARS-CoV2 IgG, neutralizing Ab (nAb)) and cellular (interferon-gamma release assay (IGRA)) immune responses were assessed at least one month after two doses of BNT162b2 mRNA vaccine. RESULTS: Among COVID-19 naïve KTRs (n = 46), 76.1% tested positive for anti-SARS-CoV-2 IgG, 54.3% for nAb, and 63% for IGRA. Serum levels of anti-SARS-CoV-2 IgG and nAb activity were significantly lower in KTRs compared to dialysis and control groups (p < 0.05 for all). Seropositivity in KTRs was independently associated with shorter transplant duration (p = 0.005), and higher eGFR (p = 0.007). IGRA titer was significantly lower than dialysis patients (p = 0.009). Twenty (43.4%) KTRs were positive for all immune parameters. Only four of 11 seronegative KTRs were IGRA-positive. COVID-19 recovered KTRs had significantly higher anti-SARS-CoV-2 IgG and nAb activity levels than COVID-19 naïve KTRs (p = 0.018 and p = 0.007, respectively). CONCLUSIONS: The humoral and cellular immune responses to SARS-CoV-2 mRNA BNT162b2 vaccine are lower in pediatric KTRs compared to dialysis patients. Further prospective studies are required to demonstrate the clinical efficacy of the mRNA vaccine in KTRs. This prospective study was registered in ClinicalTrials.gov (NCT05465863, registered retrospectively at 20.07.2022). GRAPHICAL ABSTRACT: [Figure: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00467-022-05813-w. Springer Berlin Heidelberg 2022-12-02 2023 /pmc/articles/PMC9716124/ /pubmed/36459243 http://dx.doi.org/10.1007/s00467-022-05813-w Text en © The Author(s), under exclusive licence to International Pediatric Nephrology Association 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Gulmez, Ruveyda
Ozbey, Dogukan
Agbas, Ayse
Aksu, Bagdagul
Yildiz, Nurdan
Uckardes, Diana
Saygili, Seha
Yilmaz, Esra Karabag
Yildirim, Zeynep Yuruk
Tasdemir, Mehmet
Kiykim, Ayca
Cokugras, Haluk
Canpolat, Nur
Nayir, Ahmet
Kocazeybek, Bekir
Caliskan, Salim
Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
title Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
title_full Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
title_fullStr Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
title_full_unstemmed Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
title_short Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
title_sort humoral and cellular immune response to sars-cov-2 mrna bnt162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716124/
https://www.ncbi.nlm.nih.gov/pubmed/36459243
http://dx.doi.org/10.1007/s00467-022-05813-w
work_keys_str_mv AT gulmezruveyda humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT ozbeydogukan humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT agbasayse humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT aksubagdagul humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT yildiznurdan humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT uckardesdiana humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT saygiliseha humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT yilmazesrakarabag humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT yildirimzeynepyuruk humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT tasdemirmehmet humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT kiykimayca humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT cokugrashaluk humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT canpolatnur humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT nayirahmet humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT kocazeybekbekir humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren
AT caliskansalim humoralandcellularimmuneresponsetosarscov2mrnabnt162b2vaccineinpediatrickidneytransplantrecipientscomparedwithdialysispatientsandhealthychildren